Suso Platero

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors

Josep Tabernero, Rastislav Bahleda, Rodrigo Dienstmann et al. · Journal of Clinical Oncology · 2015 · 384 citations

Medicine, Pharmacokinetics, Pharmacology +14

Identification of Candidate Molecular Markers Predicting Sensitivity in Solid Tumors to Dasatinib: Rationale for Patient Selection

Fei Huang, Karen A. Reeves, Xia Han et al. · Cancer Research · 2007 · 343 citations · Full text

Medicine, Oncology, Pharmacology +17

Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

Timothy Perera, Eleonora Jovcheva, Laurence Mévellec et al. · Molecular Cancer Therapeutics · 2017 · 340 citations · Full text

Medicine, Oncology, Pharmacology +17

Comprehensive genomic and immunological characterization of Chinese non-small cell lung cancer patients

Xu‐Chao Zhang, Jun Wang, Guoguang Shao et al. · Nature Communications · 2019 · 228 citations · Full text

Medicine, Immunology, Oncology +17

The Case for a Pre-Cancer Genome Atlas (PCGA)

Joshua D. Campbell, Sarah A. Mazzilli, Mary E. Reid et al. · Cancer Prevention Research · 2016 · 102 citations

Medicine, Cancer Biology, Oncology +15